Marcus Lind1, Irl B Hirsch2, Jaakko Tuomilehto3, Sofia Dahlqvist4, Ole Torffvit5, Nils-Gunnar Pehrsson6. 1. Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Medicine, NU-Hospital Organization, Uddevalla, Sweden. Electronic address: lind.marcus@telia.com. 2. University of Washington, Seattle, WA, USA. 3. Centre for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia. 4. Department of Medicine, NU-Hospital Organization, Uddevalla, Sweden. 5. Lund University, Lund, Sweden. 6. Statistiska Konsultgruppen, Gothenburg, Sweden.
Abstract
AIMS: Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control. METHODS:Overweight and obese patients with type 2 diabetes and impaired glycaemic control treated with MDI were randomised to liraglutide or placebo over 24 weeks. Masked continuous glucose monitoring was performed at baseline and during the trial. The primary endpoint was the change in haemoglobin A1c from baseline to week 24. Additional endpoints include changes in weight, fasting glucose, glycaemic variability, treatment satisfaction, insulin dose, hypoglycaemias, blood pressure and blood lipid levels. RESULTS: Recruitment occurred between February 2013 and February 2014. A total of 124 patients were randomised. Study completion is anticipated in August 2014. CONCLUSIONS: It is expected that the results of this study will establish whether adding liraglutide to patients with type 2 diabetes treated withMDI will improve glycaemic control, lower body weight, and influence glycaemic variability.
RCT Entities:
AIMS: Patients with type 2 diabetes are generally treated in primary care setting and as a final treatment step to obtain good glycaemic control, multiple daily insulin injections (MDI) are generally used. The aim of this study is to evaluate the effect of GLP-1 analogue liraglutide on glycaemic control in patients with type 2 diabetes treated with MDI with inadequate glycaemic control. METHODS: Overweight and obesepatients with type 2 diabetes and impaired glycaemic control treated with MDI were randomised to liraglutide or placebo over 24 weeks. Masked continuous glucose monitoring was performed at baseline and during the trial. The primary endpoint was the change in haemoglobin A1c from baseline to week 24. Additional endpoints include changes in weight, fasting glucose, glycaemic variability, treatment satisfaction, insulin dose, hypoglycaemias, blood pressure and blood lipid levels. RESULTS: Recruitment occurred between February 2013 and February 2014. A total of 124 patients were randomised. Study completion is anticipated in August 2014. CONCLUSIONS: It is expected that the results of this study will establish whether adding liraglutide to patients with type 2 diabetes treated with MDI will improve glycaemic control, lower body weight, and influence glycaemic variability.
Authors: Magnus O Wijkman; Mary Dena; Sofia Dahlqvist; Sheyda Sofizadeh; Irl Hirsch; Jaakko Tuomilehto; Johan Mårtensson; Ole Torffvit; Henrik Imberg; Aso Saeed; Marcus Lind Journal: J Clin Hypertens (Greenwich) Date: 2018-12-05 Impact factor: 3.738
Authors: Marcus Lind; Irl B Hirsch; Jaakko Tuomilehto; Sofia Dahlqvist; Bo Ahrén; Ole Torffvit; Stig Attvall; Magnus Ekelund; Karin Filipsson; Bengt-Olov Tengmark; Stefan Sjöberg; Nils-Gunnar Pehrsson Journal: BMJ Date: 2015-10-28
Authors: Sofia Dahlqvist; Elsa Ahlén; Karin Filipsson; Thomas Gustafsson; Irl B Hirsch; Jaakko Tuomilehto; Henrik Imberg; Bo Ahrén; Stig Attvall; Marcus Lind Journal: BMJ Open Diabetes Res Care Date: 2018-02-24
Authors: S S Ahmadi; K Filipsson; H Dimenäs; S S Isaksson; H Imberg; S Sjöberg; B Ahrén; S Dahlqvist; T Gustafsson; J Tuomilehto; I B Hirsch; M Lind Journal: Obes Sci Pract Date: 2019-03-18
Authors: Sheyda Sofizadeh; Henrik Imberg; Arndís F Ólafsdóttir; Magnus Ekelund; Sofia Dahlqvist; Irl Hirsch; Karin Filipsson; Bo Ahrén; Stefan Sjöberg; Jaako Tuomilehto; Marcus Lind Journal: Diabetes Ther Date: 2019-09-28 Impact factor: 2.945
Authors: Julio Rosenstock; Antonio Nino; Joseph Soffer; Lois Erskine; Andre Acusta; Jo Dole; Molly C Carr; Jason Mallory; Philip Home Journal: Diabetes Care Date: 2020-07-21 Impact factor: 19.112